Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.81 |
| ▸ | MPO | P05164 | 5/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763035 | 0.87 | HTR1A (0.76) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL739944 | 0.86 | HTR1A (0.79) | HTR1AMPOSLC6A4 | |
| SCHEMBL4261226 | 0.85 | HTR1A (0.76) | HTR1AMPOSLC6A4 | |
| SCHEMBL6347575 | 0.84 | HTR1A (0.74) | HTR1AMPOSLC6A4 | |
| SCHEMBL16441164 | 0.82 | HTR1A (1.00) | HTR1AMPO | |
| SCHEMBL9047205 | 0.82 | HTR1A (0.85) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL27836200 | 0.82 | MPO (1.00) | HTR1AMPOSLC6A4HTR7 | |
| SCHEMBL9368593 | 0.82 | HTR1A (0.92) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL8557097 | 0.81 | HTR1A (0.70) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL16432976 | 0.81 | HTR1A (1.00) | HTR1ASLC6A4HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |